In lab tests, new therapy slows spread of deadly brain tumor cells

July 27, 2015
Electron microscopic image of a single human lymphocyte. Credit: Dr. Triche National Cancer Institute

The rapid spread of a common and deadly brain tumor has been slowed down significantly in a mouse model by cutting off the way some cancer cells communicate, according to a team of researchers that includes UF Health faculty.

The technique improved the survival time for patients with glioblastoma by 50 percent when tested in a , said Loic P. Deleyrolle, Ph.D., a research assistant professor of neurosurgery in the UF College of Medicine.

Researchers focused on disrupting the cell-to-cell communication that allows cancer stem cells to spread. To do that, they targeted a channel that use to transfer molecules. By cutting off their communications pathway, the deadly cells stay in check, Deleyrolle said.

Eight UF Health researchers took part in the study, which was co-authored by Deleyrolle and published recently in the journal Cell Reports. They collaborated with researchers at the Cleveland Clinic and the University of California, Berkeley.

Glioblastoma is the most common brain tumor in adults and there is no effective long-term treatment and patients usually live for 12 to 15 months after diagnosis, according to the National Cancer Institute. Glioblastoma tumors, which are highly malignant, typically start in the largest part of the brain and can spread rapidly.

The research focused on connexin 46, a protein that is an essential component of cancer . Connexin 46 is part of intercellular channels known as a gap junction. That intercellular channel, which allows cells to exchange molecules and ions, is crucial to the growth of a glioblastoma tumor, researchers found.

"When we shut down those channels in the , we can significantly reduce the tumor-forming abilities of the cells," Deleyrolle said.

Tumor growth was significantly delayed in mouse models that were treated with a combination of the gap junction inhibitor 1-octanol and a chemotherapy drug, temozolomide. After 100 days, all of the mouse models that had the connexin 46 protein suppressed genetically were still alive. By comparison, all of the mouse models that didn't have the protein suppressed died within two months.

While the technique has yet to be tested in humans, Deleyrolle said the implications are clear and relevant. For now, a glioblastoma patient can expect to survive about 12 to 15 months. Patients can also develop a resistance to temozolomide when it is used for chemotherapy, further shortening their life expectancy.

"Any significant increase in survival time will be a meaningful improvement because the current treatments provide only weeks of efficacy" Deleyrolle said.

Another reason for optimism: All of the compounds that were tested as inhibitors are being used in humans or are in the clinical trial pipeline. Carbenoxolone is used in some European countries to treat ulcers, and 1-octanol is used as experimental treatment for tremor in the United States. That means that the amount of time needed to get the drugs into a clinical trial as a therapy for glioblastoma could be significantly shortened, Deleyrolle said.

Because gap junction inhibitors have ubiquitous functions in many organs and tissues, one of the next research steps is to determine the inhibitors' most effective and tolerable concentrations. It is also necessary to understand more about the mechanisms that make the inhibitors work, Deleyrolle said. Still, could begin within a few years, he said.

Treating is especially difficult because its cells can vary drastically, even within a single tumor—so breaking the chain of cell-to-cell communication is yet another potential weapon to fight the disease. If the new therapy is approved following a clinical trial, Deleyrolle said it would likely be put to use alongside traditional chemotherapy and radiation treatments.

Deleyrolle said he is seeking a new federal grant to continue translational research.

"When it comes down to treating such a complex disease, there isn't one magic bullet. You have to come up with complex, multiple approaches, he said.

Explore further: Researchers identify protein pathway involved in brain tumor stem cell growth

Related Stories

Researchers identify protein pathway involved in brain tumor stem cell growth

February 26, 2015
Glioblastomas are a highly aggressive type of brain tumor, with few effective treatment options. Moffitt Cancer Center researchers are one step closer to understanding glioblastoma development following the identification ...

Epigenetic driver of glioblastoma provides new therapeutic target

July 6, 2015
Cancer's ability to grow unchecked is often attributed to cancer stem cells, a small fraction of cancer cells that have the capacity to grow and multiply indefinitely. How cancer stem cells retain this property while the ...

New combination treatment strategy to 'checkmate' glioblastoma

May 8, 2015
Therapies that specifically target mutations in a person's cancer have been much-heralded in recent years, yet cancer cells often find a way around them. To address this, researchers at University of California, San Diego ...

Scientists find way to disrupt brain tumor stem cells

June 11, 2015
Some brain tumors are notoriously difficult to treat. Whether surgically removed, zapped by radiation or infiltrated by chemotherapy drugs, they find a way to return.

Progesterone could become tool versus brain cancer

June 19, 2014
(Medical Xpress)—The hormone progesterone could become part of therapy against the most aggressive form of brain cancer. High concentrations of progesterone kill glioblastoma cells and inhibit tumor growth when the tumors ...

Glioblastoma: Study ties three genes to radiation resistance in recurrent tumors

February 3, 2015
A new study identifies three genes that together enable a lethal form of brain cancer to recur and progress after radiation therapy.

Recommended for you

Tracking how multiple myeloma evolves by sequencing DNA in the blood

December 10, 2017
Although people with multiple myeloma usually respond well to treatment, the blood cancer generally keeps coming back. Following genetic changes in how the disease evolves over time will help to understand the disease and, ...

Landmark CAR-T cancer study published

December 10, 2017
Loyola University Medical Center is the only Chicago center that participated in the pivotal clinical trial of a groundbreaking cancer treatment that genetically engineers a patient's immune system to attack cancer cells.

Study finds emojis promising tool for tracking cancer patients' quality of life

December 10, 2017
In findings presented to the American Society of Hematology, Mayo Clinic researchers found that using emojis instead of traditional emotional scales were helpful in assessing patients' physical, emotional and overall quality ...

Study explores use of checkpoint inhibitors after relapse from donor stem cell transplant

December 10, 2017
Immunotherapy agents known as checkpoint inhibitors have shown considerable promise in patients with hematologic cancers who relapse after a transplant with donor stem cells. Preliminary results from the first clinical trial ...

Blood test may help predict which breast cancers will recur

December 8, 2017
A blood test five years after breast cancer treatment helped identify some women who were more likely to relapse, long before a lump or other signs appeared, a preliminary study found.

Alcohol-abuse drug Antabuse kills cancer cells

December 8, 2017
A new study in Nature by an international team including researchers from Karolinska Institutet, reports that the alcohol-abuse drug Antabuse is effective against cancer. The study also identifies a potential mechanism of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.